tweetindex
TH

Ekta Batra ✓

@ekta_batra · Mumbai · joined 14 Apr 2009

Editor, Pharmaceutical and Health, CNBC TV18. Reporting, Analysing Pharma & Health since 2008. Tweets personal. Coffee & puppy addict. Myopic bt not in my views

71 430Followers
739Following
6 696Posts total
51.7KViews on collected posts

โพสต์ล่าสุด

Neuland Labs. A stock that has risen 1.3x in 5 yrs and 50% this year. Cashing in on the complex niche cdmo opportunity the co guides for medium term growth of 20% and margins 25%. Listen in. 10.1K views · 84 likes · 8 reposts · 4 replies Open on X →
@ekta_batra @CNBCTV18Live Pump it 317 views · 2 likes · 0 reposts · 0 replies Open on X →
@ekta_batra @CNBCTV18Live Has the interview being telecasted ? @ekta_batra @CNBCTV18Live 736 views · 0 likes · 0 reposts · 1 replies Open on X →
Interviewed Saharsh Davuluri of Neuland Labs at their new peptide facility in Hyderabad. For those who want to understand the opportunity from the peptide biz, China plus one and why Neuland has such lumpy numbers...this interview is for you. Do tune in to @CNBCTV18Live for more.
19.4K views · 161 likes · 9 reposts · 2 replies Open on X →
Thank you ! 2.4K views · 6 likes · 0 reposts · 0 replies Open on X →
Biocon , a very informative interview by @ekta_batra from CNBC on their Malaysia plant , Insulin , Plan on Debt and Biosmilars portfolio , some very good questions Link: https://t.co/lPfvBkeddP 9.3K views · 24 likes · 2 reposts · 3 replies Open on X →
What’s next for Biocon? I spoke to Biocon’s CEO & MD Shreehas Tambe at its Malaysian facility about the company’s next phase of growth — from insulin and biosimilars to GLP-1s, margins, debt reduction, US opportunities and the company’s long-term strategy. Listen in. 2K views · 6 likes · 0 reposts · 0 replies Open on X →
#CNBCTV18 Global Exclusive | CNBC-TV18 At Biocon’s Malaysia Unit MD & CEO, Shreehas Tambe To @CNBCTV18News - Expect double-digit revenue growth for biosimilars to continue - Should hit $1 bn target for biosimilar business soon - Change in biosimilar policies in the US will aid h
7:36
7.4K views · 4 likes · 0 reposts · 0 replies Open on X →
What a week. 2nd award in a week! Been awarded the Best continuing coverage by a reporter at the ENBA Broadcast awards. Bronze. Couldn't have done it without the fabulous team @cnbctv18india ❤️ https://t.co/ZBeD3bDpfV
0 views · 831 likes · 17 reposts · 112 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

8 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม แสดงในวงกว้าง แต่มีผู้ชมตอบสนองน้อย.

ยอดดูมัธยฐาน4 910บัญชีนี้924ค่ามัธยฐานของ 10K–100K
การเข้าถึง, %6.87%บัญชีนี้3.62%ค่ามัธยฐานของ 10K–100K
การมีส่วนร่วม, %0.31%บัญชีนี้1.52%ค่ามัธยฐานของ 10K–100K
ตัวชี้วัดบัญชีนี้ค่ามัธยฐานของ 10K–100Kอัตราส่วน
ยอดดูมัธยฐานต่อโพสต์4 9109245.31×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)6.87%3.62%1.90×
อัตราการมีส่วนร่วม0.31%1.52%0.20×

บัญชีอื่นในช่วงนี้ →   เปรียบเทียบกับบัญชีอื่น →   ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

7.4K8 Sep
2K
9.3K9 Sep
2.4K10 Sep
19.4K22 Sep
736
31723 Sep
10.1K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.07%8 Sep
0.29%
0.32%9 Sep
0.25%10 Sep
0.90%22 Sep
0.14%
0.63%23 Sep
0.96%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes67.5%287 in total
Reposts4.5%19 in total
Replies2.4%10 in total
Quotes1.4%6 in total
Bookmarks24.2%103 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

บัญชีที่คล้ายกัน